Modelling time-varying covariates effect on survival via functional data analysis: application to the MRC BO06 trial in osteosarcoma

被引:0
作者
Marta Spreafico
Francesca Ieva
Marta Fiocco
机构
[1] Department of Mathematics,MOX
[2] Leiden University, Laboratory for Modeling and Scientific Computing
[3] University of Milano-Bicocca,Mathematical Institute
[4] Human Technopole,CHRP
[5] Leiden University Medical Center, National Center for Healthcare Research and Pharmacoepidemiology
[6] Princess Máxima Center for Pediatric Oncology,CHDS
来源
Statistical Methods & Applications | 2023年 / 32卷
关键词
Functional data analysis; Time-varying covariates; Survival analysis; Osteosarcoma;
D O I
暂无
中图分类号
学科分类号
摘要
Time-varying covariates are of great interest in clinical research since they represent dynamic patterns which reflect disease progression. In cancer studies biomarkers values change as functions of time and chemotherapy treatment is modified by delaying a course or reducing the dose intensity, according to patient’s toxicity levels. In this work, a Functional covariate Cox Model (FunCM) to study the association between time-varying processes and a time-to-event outcome is proposed. FunCM first exploits functional data analysis techniques to represent time-varying processes in terms of functional data. Then, information related to the evolution of the functions over time is incorporated into functional regression models for survival data through functional principal component analysis. FunCM is compared to a standard time-varying covariate Cox model, commonly used despite its limiting assumptions that covariate values are constant in time and measured without errors. Data from MRC BO06/EORTC 80931 randomised controlled trial for treatment of osteosarcoma are analysed. Time-varying covariates related to alkaline phosphatase levels, white blood cell counts and chemotherapy dose during treatment are investigated. The proposed method allows to detect differences between patients with different biomarkers and treatment evolutions, and to include this information in the survival model. These aspects are seldom addressed in the literature and could provide new insights into the clinical research.
引用
收藏
页码:271 / 298
页数:27
相关论文
共 125 条
  • [1] Anninga JK(2011)Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47 2431-2445
  • [2] Gelderblom H(2019)Joint model robustness compared with the time-varying covariate Cox model to evaluate the association between a longitudinal marker and a time-to-event endpoint BMC Med Res Methodol 19 222-113
  • [3] Fiocco M(2020)A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model Stat Med 39 103-445
  • [4] Kroep JR(2006)Joint models for multivariate longitudinal and multivariate survival data Biometrics 62 432-2312
  • [5] Taminiau AH(2013)Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis J Clin Oncol 31 2303-220
  • [6] Hogendoorn PC(1972)Regression models and life-tables (with discussion) J R Stat Soc B 34 187-736
  • [7] Egeler RM(2011)Joint model with latent state for longitudinal and multistate data Biostat 12 723-278
  • [8] Arisido MW(2015)Cox regression models with functional covariates for survival data Stat Model 15 256-2195
  • [9] Antolini L(2015)Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group Stat Med 34 2181-2545
  • [10] Bernasconi D(1999)Assessment and comparison of prognostic classification schemes for survival data Stat Med 18 2529-112